Press releases
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo and Sobi agree to advance feasibility study with AmorphOX
More ▼
Key statistics
On Wednesday, Orexo AB (ORXOF:QXE) closed at 1.50, -23.08% below its 52-week high of 1.95, set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.50 |
---|---|
High | 1.50 |
Low | 1.50 |
Bid | -- |
Offer | -- |
Previous close | 1.50 |
Average volume | 1.00k |
---|---|
Shares outstanding | 34.71m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 586.61m SEK |
EPS (TTM) | -3.73 SEK |
Data delayed at least 15 minutes, as of Apr 24 2024 14:30 BST.
More ▼